CSIMarket
 


Titan Pharmaceuticals Inc   (TTNP)
Other Ticker:  
 

Titan Pharmaceuticals Inc 's Quick Ratio

TTNP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Titan Pharmaceuticals Inc 's Cash & cash equivalent grew by 7610.48 % in the III Quarter 2023 sequentially, faster than Current Liabilities, this led to improvement in Titan Pharmaceuticals Inc 's Quick Ratio to 4.34, above Titan Pharmaceuticals Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 83 other companies have achieved higher Quick Ratio than Titan Pharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 651, from total ranking in the second quarter 2023 at 4032.

Explain Quick Ratio?
How much Cash & cash equivalents TTNP´s has?
What are TTNP´s Current Liabilities?


TTNP Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -29.05 % -26.86 % 7.42 % -1.46 % 4.53 %
Y / Y Cash & cash equivalent Change 81.93 % -98.36 % -86.04 % -51.35 % -54.03 %
Quick Ratio MRQ 4.34 0.06 0.46 1.12 1.69
TTNP's Total Ranking # 651 # 4032 # 2525 # 1752 # 1574
Seq. Current Liabilities Change 1.08 % -24.56 % -6.96 % -0 % 4.2 %
Seq. Cash & cash equivalent Change 7610.48 % -90.76 % -61.32 % -34 % -30.69 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 84
Healthcare Sector # 358
Overall Market # 651


Quick Ratio Statistics
High Average Low
5.93 2.05 0.06
(Sep 30 2017)   (Jun 30 2023)




Financial Statements
Titan Pharmaceuticals Inc 's Current Liabilities $ 2 Millions Visit TTNP's Balance sheet
Titan Pharmaceuticals Inc 's Cash & cash equivalent $ 8 Millions Visit TTNP's Balance sheet
Source of TTNP's Sales Visit TTNP's Sales by Geography


Cumulative Titan Pharmaceuticals Inc 's Quick Ratio

TTNP's Quick Ratio for the trailling 12 Months

TTNP Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -29.05 % -26.86 % 7.42 % -1.46 % 4.53 %
Y / Y Cash & cash equivalent TTM Growth 81.93 % -98.36 % -86.04 % -51.35 % -54.03 %
Quick Ratio TTM 1.4 0.9 1.46 2.18 2.48
Total Ranking TTM # 1161 # 1603 # 1380 # 1291 # 1219
Seq. Current Liabilities TTM Growth 1.08 % -24.56 % -6.96 % -0 % 4.2 %
Seq. Cash & cash equivalent TTM Growth 7610.48 % -90.76 % -61.32 % -34 % -30.69 %


On the trailing twelve months basis TTNP Cash & cash equivalent soared by 81.93 % in III Quarter 2023 year on year, while Current Liabilities rose to $2 millions, this led to increase in in Titan Pharmaceuticals Inc 's Quick Ratio to 1.4, Quick Ratio remained below TTNP average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 165 other companies have achieved higher Quick Ratio than Titan Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3087 to 3600.

Explain Quick Ratio?
How much Cash & cash equivalents TTNP´s has?
What are TTNP´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 166
Healthcare Sector # 1012
Within the Market # 651


trailing twelve months Quick Ratio Statistics
High Average Low
4.1 2.03 0.89
(Sep 30 2017)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Scholar Rock Holding Corp  11.19 $ 218.635  Millions$ 19.530  Millions
Kymera Therapeutics Inc   11.11 $ 357.825  Millions$ 32.219  Millions
Protara Therapeutics Inc   10.93 $ 74.034  Millions$ 6.775  Millions
Vir Biotechnology Inc   10.29 $ 1,698.921  Millions$ 165.050  Millions
Ikena Oncology Inc   10.22 $ 196.933  Millions$ 19.271  Millions
Inhibrx Inc   9.99 $ 337.327  Millions$ 33.760  Millions
Invivyd Inc   9.89 $ 264.885  Millions$ 26.791  Millions
Cardiff Oncology inc   9.77 $ 81.363  Millions$ 8.330  Millions
Black Diamond Therapeutics Inc   9.57 $ 144.256  Millions$ 15.066  Millions
Solid Biosciences Inc   9.03 $ 142.884  Millions$ 15.816  Millions
Jasper Therapeutics Inc   8.72 $ 103.867  Millions$ 11.906  Millions
Springworks Therapeutics Inc   8.40 $ 422.419  Millions$ 50.283  Millions
Turnstone Biologics Corp   8.35 $ 109.221  Millions$ 13.081  Millions
Century Therapeutics inc   8.29 $ 169.505  Millions$ 20.435  Millions
Autolus Therapeutics Plc  8.00 $ 256.415  Millions$ 32.049  Millions
Atyr Pharma Inc   7.93 $ 102.131  Millions$ 12.881  Millions
Monte Rosa Therapeutics Inc   7.89 $ 178.477  Millions$ 22.609  Millions
Tscan Therapeutics Inc   7.49 $ 215.423  Millions$ 28.775  Millions
Tracon Pharmaceuticals Inc   7.19 $ 7.763  Millions$ 1.080  Millions
Immunovant Inc   6.81 $ 269.928  Millions$ 39.645  Millions
Palisade Bio Inc   6.74 $ 15.312  Millions$ 2.273  Millions
Passage Bio inc   6.70 $ 132.780  Millions$ 19.811  Millions
Humacyte Inc   6.61 $ 99.986  Millions$ 15.137  Millions
Surrozen Inc   6.51 $ 43.432  Millions$ 6.672  Millions
Allovir Inc   6.45 $ 213.318  Millions$ 33.066  Millions
Tenaya Therapeutics Inc   6.28 $ 121.753  Millions$ 19.377  Millions
Ginkgo Bioworks Holdings Inc   6.23 $ 1,049.244  Millions$ 168.462  Millions
Inhibikase Therapeutics Inc   6.14 $ 16.832  Millions$ 2.742  Millions
Zura Bio Limited  6.11 $ 103.859  Millions$ 17.012  Millions
Athira Pharma Inc   6.04 $ 172.948  Millions$ 28.622  Millions

Date modified: 2024-01-10T05:56:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com